Percheron Therapeutics Ltd (PER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Percheron Therapeutics Ltd (PER) has a cash flow conversion efficiency ratio of -0.716x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.16 Million ≈ $-5.07 Million USD) by net assets (AU$10.00 Million ≈ $7.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Percheron Therapeutics Ltd for the company's overall valuation and market capitalisation.
Percheron Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Percheron Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Percheron Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Percheron Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore PER cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STS Global Income & Growth Trust PLC
LSE:STS
|
0.011x |
|
Metalore Resources Ltd
V:MET
|
0.024x |
|
Victorian Plumbing Group PLC
LSE:VIC
|
0.238x |
|
1844 Resources Inc
V:EFF
|
0.136x |
|
HYDRIX Ltd
AU:HYD
|
0.279x |
|
Prima Cakrawala Abadi PT
JK:PCAR
|
0.183x |
|
Mountain Province Diamonds Inc
TO:MPVD
|
2.361x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Percheron Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Percheron Therapeutics Ltd from 2002 to 2025. View latest Percheron Therapeutics Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$10.00 Million ≈ $7.08 Million |
AU$-15.64 Million ≈ $-11.07 Million |
-1.564x | -44.74% |
| 2024-06-30 | AU$9.36 Million ≈ $6.62 Million |
AU$-10.12 Million ≈ $-7.16 Million |
-1.080x | -32.22% |
| 2023-06-30 | AU$9.98 Million ≈ $7.06 Million |
AU$-8.15 Million ≈ $-5.77 Million |
-0.817x | -121.33% |
| 2022-06-30 | AU$21.14 Million ≈ $14.96 Million |
AU$-7.81 Million ≈ $-5.52 Million |
-0.369x | +63.76% |
| 2021-06-30 | AU$5.73 Million ≈ $4.05 Million |
AU$-5.83 Million ≈ $-4.13 Million |
-1.019x | -16.98% |
| 2020-06-30 | AU$4.53 Million ≈ $3.21 Million |
AU$-3.95 Million ≈ $-2.79 Million |
-0.871x | +16.46% |
| 2019-06-30 | AU$2.81 Million ≈ $1.99 Million |
AU$-2.93 Million ≈ $-2.07 Million |
-1.042x | -91.14% |
| 2018-06-30 | AU$4.22 Million ≈ $2.99 Million |
AU$-2.30 Million ≈ $-1.63 Million |
-0.545x | +65.32% |
| 2017-06-30 | AU$1.85 Million ≈ $1.31 Million |
AU$-2.91 Million ≈ $-2.06 Million |
-1.572x | -255.40% |
| 2016-06-30 | AU$4.58 Million ≈ $3.24 Million |
AU$-2.03 Million ≈ $-1.43 Million |
-0.442x | -347.26% |
| 2015-06-30 | AU$7.09 Million ≈ $5.02 Million |
AU$1.27 Million ≈ $897.81K |
0.179x | +112.01% |
| 2014-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-3.11 Million ≈ $-2.20 Million |
-1.489x | -144.27% |
| 2013-06-30 | AU$4.65 Million ≈ $3.29 Million |
AU$-2.83 Million ≈ $-2.00 Million |
-0.610x | -33.48% |
| 2012-06-30 | AU$5.27 Million ≈ $3.73 Million |
AU$-2.41 Million ≈ $-1.70 Million |
-0.457x | +50.63% |
| 2011-06-30 | AU$2.02 Million ≈ $1.43 Million |
AU$-1.87 Million ≈ $-1.32 Million |
-0.925x | +6.96% |
| 2010-06-30 | AU$1.34 Million ≈ $951.04K |
AU$-1.34 Million ≈ $-945.75K |
-0.994x | -18.94% |
| 2009-06-30 | AU$3.93 Million ≈ $2.78 Million |
AU$-3.28 Million ≈ $-2.32 Million |
-0.836x | -55.71% |
| 2008-06-30 | AU$6.33 Million ≈ $4.48 Million |
AU$-3.40 Million ≈ $-2.41 Million |
-0.537x | -20.59% |
| 2007-06-30 | AU$6.02 Million ≈ $4.26 Million |
AU$-2.68 Million ≈ $-1.90 Million |
-0.445x | +1.08% |
| 2006-06-30 | AU$8.79 Million ≈ $6.22 Million |
AU$-3.96 Million ≈ $-2.80 Million |
-0.450x | +12.43% |
| 2005-06-30 | AU$10.86 Million ≈ $7.69 Million |
AU$-5.59 Million ≈ $-3.95 Million |
-0.514x | -298.62% |
| 2004-06-30 | AU$17.13 Million ≈ $12.12 Million |
AU$-2.21 Million ≈ $-1.56 Million |
-0.129x | +57.16% |
| 2002-06-30 | AU$13.48 Million ≈ $9.54 Million |
AU$-4.06 Million ≈ $-2.87 Million |
-0.301x | -- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more